Nexcelom Bioscience Launches Cellometer^® Vision Automated Cell Counter with Fluorescence Detection

Nexcelom Bioscience, LLC of Lawrence, MA, a manufacturer of instruments for cell-based assays used in cancer research and drug discovery, launched its Cellometer^® Vision, an innovative automatic cell counter with multi-mode imaging analysis, at the AACR (American Association for Cancer Research) Annual Meeting in San Diego, CA. Vision is the latest addition to the line of Cellometer automated cell counters, which improves throughput by automating tedious manual counting procedures.

The Vision incorporates the same features and functionality as other Cellometer instruments, automating not only the counting of total cells, but adds the ability to detect and quantify fluorescing cells as well. The Cellometer Vision system is ideal for difficult cell assay applications such as monitoring GFP transfection rates, quantifying the presence of FITC surface markers, directly counting white blood cells in whole blood, and measuring the concentration and sizes of adipocytes.

Cellometer Vision simplifies the acquisition of fluorescent and total cellular images versus traditional methods, by making the technology easy-to-use and affordable enough to be used routinely on every lab bench. Cellometer Vision has a compact footprint and its ease-of-use is the cornerstone of the Cellometer line. After pipetting 20µL of sample into the Cellometer disposable counting chamber, and inserting it into the instrument, the patent pending dual-mode imaging method acquires bright field and fluorescent cell images, and software automatically measures cell sizes, fluorescence data, cell concentration and viability. A comprehensive set of data, including histograms and scatter-plots, is generated without complex manipulation. The instrument requires no clean-up, or other time-consuming maintenance procedures.

“Listening to our customers has made Nexcelom Bioscience what it is today, and it was our current users that brought to our attention the complexity, costs and inconvenience involved with counting fluorescent labeled cells, for applications such as calculating GFP Transfection rates”, said Jean Qiu, PhD, President of Nexcelom Bioscience. “We wanted the Vision to do for fluorescence assays what the Cellometer Auto T4 did for manual cell counting: deliver simple automation to the lab bench so researchers can spend more time on interpreting data, rather than generating it.” Jean concluded, “Cellometer Vision accomplishes that, and by making this technology easy-to-use and available in every lab, these techniques can be more readily applied in day-to-day research, accelerating breakthroughs in cancer research, and drug discovery & development.”